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The potential role of coffee as a hepatoprotective substance for chronic liver diseases
has  been widely discussed. Our main aim was to evaluate the effect of coffee intake
regarding clinical, biochemical tests and liver biopsy data in treatment naïve patients with
chronic hepatitis C. One hundred and thirty-six patients with chronic hepatitis C, diag-
nosed through liver biopsy, or by means of clinical, ultrasound or endoscopic signs of
cirrhosis, were assessed by determination of biochemical tests, metabolic and morpho-
logical alterations. Food frequency was scrutinized by using a structured questionnaire.
Coffee intake represented more than 90% of the total daily caffeine, and the 75th percentile
was 4-Brazilian coffee-cup/day (≥255 mL/day or ≥123 mg caffeine/day). According to caf-
feine intake, patients were divided into two groups (< or ≥123 mg  caffeine/day). Patients
with higher ingestion of caffeine had lower serum levels of aspartate aminotransferase (×
upper limit of normal) (1.8 ± 1.5 vs 2.3 ± 1.5, p = 0.04), lower frequencies of advanced (F3, F4)
ﬁbrosis (23.5% vs 54.5%, p < 0.001) and of histological activity grade (A3, A4) observed in liver
biopsies (13.8% vs 36.9%, p < 0.001). By multivariate logistic regression, ﬁbrosis was inde-
pendently associated with caffeine intake (OR– 0.16; 95%CI – 0.03–0.80; p = 0.026), -glutamil
transferase serum levels and morphological activity. But only ﬁbrosis was associated with
histological activity. In conclusion caffeine consumption greater than 123 mg/day was asso-ciated with reduced hepatic ﬁbrosis. In addition, this study supports the assumption that
coffee intake has hepatoprotective beneﬁts for Brazilian patients with chronic hepatitis C,
even in lower doses than that of American and European population intake.
antimutation activities, and diterpenes (cafestol and kah-
6IntroductionHepatitis C virus (HCV) infects chronically 130–170 million of
the world’s population.1 In Brazil, the prevalence of HCV infec-
tion ranges from 1 to 2%.2 Evidence suggests that caffeine
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may have hepatoprotective properties. In addition to caffeine,
coffee contains chlorogenic acid, which has antioxidant and
3–5 São Paulo, SP, Brazil.
rise@terra.com.br (E.R. Parise).
weol) with anticarcinogenic properties.
Coffee consumption, speciﬁcally with caffeine, has shown
to be associated with a decreased risk of liver-associated
a.
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nzyme elevations.7–9 Also, many  studies have reported an
nverse relationship between coffee drinking and the risk
f liver cirrhosis.10–12 Some cohort13–15 and case-control
tudies,12,16–18 as well as two meta-analyses,19,20 suggested
n inverse relationship between coffee drinking and the risk
f hepatocellular carcinoma. Two studies showed that regular
offee intake (above a threshold of 308 or 408 mg/day of caf-
eine) was associated with less severe hepatic ﬁbrosis or with
educed histological activity in patients with chronic hepatitis
.21,22 Another recent study reported that higher coffee intake
ad a protective effect on non-alcoholic fatty liver disease23
nd signiﬁcant risk reduction for ﬁbrosis among non-alcoholic
teatohepatitis patients.24
Nowadays, the potential role of coffee as a hepatopro-
ective substance for chronic liver diseases has been widely
iscussed. Furthermore, the consumption of coffee by the
razilian population has some peculiar characteristics in com-
arison with the European and American population. Thus,
he main aim of this study was to evaluate the effect of cof-
ee intake on clinical, biochemical and liver biopsy data in
reatment naïve patients with chronic hepatitis C.
aterials  and  methods
atients
ne hundred thirty-six treatment naïve patients with chronic
epatitis C were selected from the clinic of Gastroenterol-
gy Division Federal University of Sao Paulo, Escola Paulista
e Medicina, between January 2009 and December 2011.
hey were enrolled into the study if they met  the follow-
ng criteria: positivity for serum HCV RNA; liver biopsy or
iagnosis of hepatic cirrhosis based on clinical, ultrasound
r endoscopic characteristics as well as the absence of pre-
ious antiviral therapy for chronic hepatitis C. Patients using
rugs containing caffeine, co-infected with hepatitis B virus
serum HBsAg positive) or human immunodeﬁciency virus,
xcessive alcohol consumption (ethanol dose ≥20 g/day for
omen and ≥40 g/day for men), concomitant liver diseases,
ecompensated diabetes mellitus and clinically or biochem-
cally recognized systemic diseases were excluded from this
tudy.
The study was approved by the ethics committee of São
aulo Hospital of UNIFESP. All participants received detailed
nformation about the study and gave written informed
onsent according to the norms of the Helsinki declara-
ion.
aboratory  tests
-Glutamil transferase (GT), alanine aminotransferase (ALT),
spartate aminotransferase (AST) and alkaline phosphatase
ALP) were determined by an automated kinetic method. Lipid
roﬁle (total cholesterol, high-density lipoprotein choles-
erol (HDL-C) triglycerides, low-density lipoprotein cholesterol
LDL-C) and fasting glucose were measured by an automated
olorimetric method. Insulin concentration was determined
y immunoﬂuorometric assay and insulin resistance was
alculated by homeostasis model assessment (HOMA-IR)4;1 8(2):170–176 171
using the following formula: fasting insulin (U/mL)  × fasting
glycemia (mmol/L)/22.5.25
Liver  histopathology
All liver biopsy specimens were ﬁxed in formalin, embedded in
parafﬁn and routinely processed for histological analysis. His-
tological scoring was performed according to the guidelines
of the Brazilian Society of Pathology and Hepatology where
the ﬁbrosis score is similar to the Metavir classiﬁcation, and
inﬂammation semi-quantiﬁed as follows: grading of portal
inﬂammation (0–4); interface hepatitis (0–4) and parenchy-
mal  necro-inﬂammatory lesions (0–4). The assessment of the
inﬂammatory degree was done by the grade of interface hep-
atitis or with the sum of the portal inﬂammation, interface
hepatitis and parenchymal lesion grade (histology activity
index).26
Development  of  the  caffeine  questionnaire
Clinical interviews were performed by a dietitian using a
structured questionnaire. A food frequency questionnaire was
developed, using the format of the questionnaire used in
the Health Professionals Follow-up Study Questionnaire,27
to evaluate caffeine intake. Patients were asked to quantify
the frequency and the quantity of consumption of caffeine-
containing products, including regular and diet carbonated
soft drink beverages, regular coffee, decaffeinated coffee, black
or green tea, cocoa/hot chocolate, caffeine-fortiﬁed drinks or
chocolate candies. Consumption frequency was quantiﬁed as
daily, weekly, monthly, occasionally or never. This question-
naire included data about caffeine-containing medications,
coffee consumption time, the ﬁltration method (paper or
cloth), quantity of coffee used per month and the number of
family members who drink coffee.
Statistical  analysis
Total caffeine intake from foods and beverages (mg/day) was
calculated by summing up caffeine content based on esti-
mates from the published literature: regular coffee (137 mg
per 8-oz cup),22,28,29 decaffeinated coffee (2 mg per 8-oz cup)
(USDA), espresso coffee (64 mg  per 1-oz cup) (USDA), instant
coffee (63 mg  per 8-oz cup) (USDA), green tea (30 mg  per 7-
oz cup),30,31 chocolate candy bars (7.4 mg  per 30 g).29 Daily
caffeine intake for each patient was calculated from total cof-
fee intake according to the frequency questionnaire. Caffeine
intake was dichotomized above and below the 75th percentile
according to the threshold for the cohort of the previous
study.22
Chi-square or Fisher’s exact test was performed for cat-
egorical variables, Mann–Whitney for continuous variables
(non-parametric test) and “t” Student test (categorical vari-
ables, parametric test). Spearman’s correlation was performed
to evaluate the level of correlation between the variables
studied. Univariate analysis and logistic regression were per-
formed to identify independent predictors.
Statistical analyses were carried out using the SPSS 10.0
for Windows (SPSS, Inc., Chicago, IL, USA), with the level of
signiﬁcance set at p ≤ 0.05.
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Table 1 – Baseline characteristics of the patients.
Variables Total patients
n = 136, 100%
Gender, male/female (%) 51.5/48.5
Age (years) 52 ± 13
Body mass index (kg/m2) 27 ± 4.6
ALT (× ULN) 2.2 ± 1.7
AST (× ULN) 2.2 ± 1.5
GT (× ULN) 3.1 ± 3.2
Glucose, mg dL−1 105.4 ± 38.2
HOMA-IR 2.6 ± 2.6
HDL cholesterol, mg dL−1 45.1 ± 14.8
Triglycerides, mg dL−1 99.3 ± 42.8
HCV genotype (%)
1 67.6
2 and 3 32.4
Fibrosis score, (%)
F0 8.8
F1 27.9
F2 16.2
F3 10.3
F4 36.8
Activity grade, (%)
A0 8.8
A1 21.2
A2 38.1
A3 25.7
A4 6.2
Steatosis, (%)
Yes 56.6
No 43.4
Caffeine consumption (mg/day) 112.1 ± 178.8
Lifetime caffeine consumption, (%)
≥20 years 100%
Methods for coffee, (%)
Paper ﬁlter 70.6
Cloth ﬁlter 29.4
Smoking, (%)
Yes 29.4
No 70.6
Continuous data are expressed as mean ± standard deviation and
categoric data are expressed as percentage. Abbreviations:  ALT,
alanine aminotransferase; AST, aspartate aminotransferase; (GT,
(-glutamyl transferase; HOMA-IR, homeostasis model assessment
of insulin resistance (fasting insulin [(U/mL] × fasting glycemia
Table 2 – Characteristics of the patients according to
caffeine intake.
Parameters Caffeine intake p-Value
<123 mg/day ≥123 mg/day
(n = 102) (n = 34)
Gender, male/female (%) 49/51 59/41 0.43
Age (years) 51.7 ± 12.6 51.1 ± 13.9 0.89
Body mass index (kg/m2) 27.1 ± 4.5 27.4 ± 5.5 1.0
ALT (× ULN) 2.2 ± 1.5 2.2 ± 2.1 0.41
AST (× ULN) 2.3 ± 1.5 1.8 ± 1.5 0.04
GT (× ULN) 3.3 ± 3.3 2.9 ± 2.4 0.56
Glucose, mg dL−1 105.3 ± 35.0 106.0 ± 47.5 0.26
HOMA-IR 2.6 ± 2.6 2.4 ± 2.6 0.39
HDL cholesterol, mg dL−1 45.5 ± 14.9 43.8 ± 14.6 0.74
Triglycerides, mg dL−1 99.1 ± 40.5 104.4 ± 50.0 0.51
HCV genotype, (%)
1 67.6 66.7 0.99
2 and 3 32.4 33.3
Fibrosis score, (%)
F0 6.9 14.7
F1 23.5 41.2
F2 14.7 20.6 <0.001
F3 10.8 8.8
F4 44.1 14.7
Activity grade, (%)
A0 7.1 13.8
A1 17.9 31.0
A2 38.1 38.0 <0.001
A3 28.6 17.2
A4 8.3 0
Steatosis, (%)
Yes 45.7 37.5 0.562
No 54.3 62.5
Methods for coffee, (%)
Paper ﬁlter 31.4 29.4 0.88
Cloth ﬁlter 68.6 70.6
Smoking, (%)
Yes 28.4 32.4 0.65
No 71.6 67.6
Continuous data are expressed as mean ± standard deviation and
categoric data are expressed as percentage. Abbreviations: ALT,
alanine aminotransferase; AST, aspartate aminotransferase; GT,
-glutamyl transferase; HOMA-IR, homeostasis model assessment
of insulin resistance (fasting insulin [U/mL] × fasting glycemia
[nmol/L]/22.5); HDL cholesterol, high-density lipoprotein choles-[nmol/L]/22.5); HDL cholesterol, high-density lipoprotein choles-
terol; ULN, upper limit of normal.
Results
Table 1 shows baseline characteristics of the patients. Sev-
enty patients were men  (51.5%), the mean age of the overall
group was 52 ± 13 years and the mean body mass index (BMI)
was 27 ± 4.6 kg/m2 and HCV genotype 1 (67.2%) was predom-
inant. Of the 136 patients, 113 patients were biopsied and
23 patients were considered to have liver cirrhosis on the
grounds of clinical and endoscopic and/or ultrasound exam-
ination. Activity grades ≥3 and 4 and ﬁbrosis stage ≥3 and 4
were present in 47.1% and 31.9% of patients, respectively. Theterol; ULN, upper limit of normal.
average estimated daily consumption of caffeine from foods
and beverages was 115.5 mg  and of all the caffeine consumed,
96.6% came from regular coffee, 2.8% from caffeinated soft
drinks, 0.4% from chocolate and 0.2% from tea.
The patients were divided into groups, according to the
75th percentile (123 mg  of caffeine) (Table 2). The two  groups
did not present signiﬁcant differences in demographic or
anthropometric characteristics. However, signiﬁcant reduc-
tion in AST serum level (× ULN) (1.8 ± 1.5 vs 2.3 ± 1.5, p = 0.04)
was observed in the group with high caffeine ingestion. Caf-
feine intake related to greater than 4-Brazilian coffee-cup/day
(≥255 mL/day or ≥123 mg caffeine/day) was also associated
with lower frequencies of advanced ﬁbrosis (F3, F4) (23.5%
vs 54.5%, p < 0.001) and histological activity grade (A3, A4)
observed in liver biopsies (13.8% vs 36.9%, p < 0.001) (Table 2).
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Table 3 – Univariate and logist regression analysis of factors associated with ﬁbrosis.
Parameters Univariada OR 95% IC Multivariate
p value p value
Caffeine consumption 0.004 0.16 0.03–0.80 0.026
Gender 0.036 0.36 0.10–1.27 0.111
Age 0.315
AST (× ULN) <0.001 2.06 0.40–10.52 0.387
ALT (× ULN) 0.012 0.98 0.20–4.71 0.982
GT (× ULN) <0.001 4.03 1.06–15.36 0.041
Cholesterol total 0.010 0.45 0.13–1.56 0.206
HOMA-IR 0.001 2.81 0.76–10.46 0.123
Activity grade <0.001 12.22 3.28–45.54 <0.001
Steatosis 0.214
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To clarify the effect of the caffeine intake on liver ﬁbro-
is and histological activity in the hepatitis C evolution,
oth univariate analysis and logistic regression were per-
ormed. In univariate analysis, advanced ﬁbrosis (ﬁbrosis
tage ≥3 and 4) was signiﬁcantly associated to caffeine
ntake (p = 0.004), gender (p = 0.036), AST serum level (p < 0.001),
LT serum level (p = 0.012), GT serum level (p < 0.001), total
holesterol serum level (p = 0.01), HOMA-IR (p = 0.001) and his-
ological activity (p < 0.001). By multivariate logistic regression,
dvanced ﬁbrosis was independently associated with caffeine
ntake (OR = 0.16; 95% CI: 0.03–0.80; p = 0.026); GT serum level
OR = 4.03; CI 95%: 1.06–15.36; p = 0.041) and histological activity
OR = 12.22; CI 95%: 3.28–45.54; p < 0.001) (Table 3).
A similar analysis for advanced histological activity grade
bserved in liver biopsies (activity grades ≥3 and 4) was per-
ormed. By univariate analysis, severe histological activity
rade was signiﬁcantly associated to caffeine intake (p = 0.026),
ST serum level (p = 0.001), ALT serum level (p = 0.037), total
holesterol serum level (p = 0.015) and liver ﬁbrosis (p < 0.001).
owever, by multivariate logistic regression, only liver ﬁbrosis
as associated with histological activity grade. No associa-
ion could be found between histological activity and caffeine
ntake (Table 4).
iscussionith the threshold of the 75th percentile to identify patients
ith greater caffeine intake, we  found that these HCV
atients presented lower levels of serum AST levels and lower
Table 4 – Univariate and logistic regression analysis of factors a
Parameters Univariada 
p value 
Caffeine consumption 0.026 
AST (× ULN) 0.001 
ALT (× ULN) 0.037 
Cholesterol total 0.015 
Fibrosis <0.001 1
Steatosis 0.186
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransfeferase; GT, -glutamyl transferase; HOMA-IR, homeostasis model
ia [nmol/L]/22.5); ULN, upper limit of normal.
frequency of advanced inﬂammatory activity and ﬁbrosis
degree when compared with those with lower caffeine intake.
These ﬁndings are consistent with previous studies suggesting
a liver protective effect of caffeine in patients with other liver
diseases.8,9,21,22,32,33 In order to assess the impact of caffeine
ingestion on histological parameters, univariate and multi-
variate logistic regression were performed with the degree of
ﬁbrosis as a continuous variable, in order to clarify the real
impact of caffeine in liver disease progression. In such an
analysis, daily caffeine intake higher than 123 mg (4-Brazilian
coffee-cup/day) stood out as an independent predictor of a
lower risk of advanced ﬁbrosis, together with serum GT level
and histological activity, two parameters previously described
as independent risk factors for ﬁbrosis. Although signiﬁcant in
univariate analysis, caffeine ingestion could not be associated
with inﬂammatory activity, assessed by interface hepatitis or
even by the histology activity index (data not shown), by logis-
tic regression. It is possible that the exclusion of 17% of the
patients from the cohort (those with overt cirrhosis and no
liver biopsy performed) had reduced the strength of the anal-
ysis for the association between activity and caffeine intake,
but the association between ﬁbrosis degree and daily caffeine
ingestion persisted even after the exclusion of these patients
with overt cirrhosis.
Comparing this study with those previously published, it
became clear that there is a difference between the pattern
of daily caffeine ingestion between Brazilian, European and
American patients with HCV chronic infection. Coffee intake
accounts for more  than 95% of the daily caffeine ingestion
in our cohort while it has been reported to be around 70%
ssociated with activity grade.
OR 95% IC Multivariate
p value
0.91 0.22–3.72 0.892
1.22 0.24–6.21 0.812
1.24 0.29–5.29 0.777
0.52 0.18–1.56 0.246
3.21 3.74–46.74 <0.001
rase; GT, -glutamyl transferase; ULN, upper limit of normal.
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among American patients; in this study, the threshold of the
75th percentile was ≥123 mg  caffeine/day (≥255 mL/day or 4-
Brazilian coffee-cup/day), while other studies report a cut-off
of 308 mg  caffeine/day22 or 407 mg  caffeine/day.21 These dif-
ferences allowed us to demonstrate that a lower cut-off of
caffeine intake has liver protective beneﬁts. Protective effect
of caffeine on liver was signiﬁcant and evaluated as a con-
tinuous variable, categorized as coffee-cup equivalents, or
dichotomized above or below the 75th percentile for the study
population. Categorization of caffeine intake by coffee-cup
equivalents or quartile suggested that the protective effect of
caffeine may not be linear, and there appears to be a threshold
effect. Approximately 4-Brazilian coffee-cup/day, was neces-
sary to have an effect on ﬁbrosis progression in these patients
with chronic hepatitis C. Clariﬁcation of whether there is a
hepatoprotective threshold and whether the beneﬁts eventu-
ally plateau with further consumption will be important for
understanding the biology and potentially for therapeutic rec-
ommendations. Furthermore, these results strongly support
the assumption that coffee’s caffeine has hepatoprotective
beneﬁts in Brazilian patients with chronic hepatitis C, since,
in this cohort, coffee was almost the only source of caffeine
intake.
Coffee contains a variety of chemical compounds, includ-
ing caffeine, chlorogenic acid, quinides, trigonelline and
lignin. The standardization of these compounds’ concentra-
tion in a cup of coffee is difﬁcult and the food frequency
questionnaires are useful tools, but are subject to misclas-
siﬁcation. To our knowledge, this is the ﬁrst study able to
examine the preparation and serving methods of coffee. For
this reason, coffeine consumption via the number of con-
sumed cups of coffee may correctly reﬂect the differences
between the groups. Analyzing methods used to collect dietary
data on coffee and caffeine intake in previous studies,21,22,32,34
we  observed that several authors had used only the food fre-
quency questionnaire, which was self-administered or applied
by the health-professional nurse. In the present study, in order
to further investigate the dietary intake of coffee and caffeine,
24-h dietary recall was associated with a food frequency ques-
tionnaire and both applied by nutritionists. In professional
practice, nutritionists are able to develop speciﬁc actions.35
The food frequency questionnaire is the most widely used in
population studies and more  appropriate to classify individ-
uals according to intake of foods or nutrients.29
Here, patients with higher caffeine intake had also lower
AST levels. Similarly, a study enrolling Japanese patients with
no previous liver dysfunction reported that coffee intake
was inversely associated to AST and ALT serum concentra-
tions, regardless of age, BMI, alcohol intake and smoking.7
Another study identiﬁed lower ALT levels in patients with
higher caffeine intake and it suggested that caffeine has
an antioxidant inhibiting lipid peroxidation role and conse-
quently, the formation of free radicals.8 Previous studies have
shown that increased coffee consumption is associated with
lower liver enzymes, reduced rates of liver cancer, and pos-
sibly even reduced hepatic decompensation and liver-related
8,9,11,33,35mortality.
The mechanisms underlying potential hepatoprotective
effects of caffeine in patients with chronic hepatitis C remain
to be determined. Caffeine is a purine alkaloid, acting through 1 4;1  8(2):170–176
the antagonism of adenosine receptors A1 and A2.23 Recent
studies have demonstrated that adenosine, acting at A2
receptors, stimulates hepatic stellate cell-mediated ﬁbrosis
of the liver29,36–39 by increasing production of collagen I
and III (the collagens present in scar tissue) via two distinct
mitogen-activated protein kinase (MAPK)-dependent path-
ways, extracellular signal-regulated kinase 1/2 (ERK1/2) and
p38MAPK, respectively.40 Interestingly, caffeine, the most
widely used drug in the world, mediates most of its phar-
macological effects by non-selectively blocking adenosine
receptors, including A2 receptors, and can prevent hepatic
ﬁbrosis in animal models.41,42 Several reports suggest caffeine
and other constituents of coffee, as Kahweol and cafesterol,
possess antioxidant properties.43–45 Studies in mice and rats
as well as with human hepatoma cell lines have shown that
coffee and some of its major components (caffeine, cafestol,
and kahweol) alter expression and activity of enzymes
involved in xenobiotic metabolisms.46,47 Inhibition of phase
I enzymes and up-regulation of phase II enzymes such as
glutathione-S-transferase have been reported, both of which
would favor reduced accumulation of toxic metabolites
within hepatocytes.46 Pre-treatment with cafestol and kah-
weol protected mice from carbon tetrachloride hepatotoxicity
by inhibiting cytochrome CYP 2E1, the enzyme responsible for
carbon tetrachloride bioactivation.48 With respect to caffeine
speciﬁcally, a study reported that caffeine inhibits expression
of a connective tissue growth factor (CTGF) by interfering with
the transforming growth factor beta (TGF) signaling through
the similar to mothers against decapentaplegic in drosophila
(SMAD) pathway.49 Caffeine was also found to up-regulate
peroxisome proliferator-activated receptor gamma (PPAR)
levels, which further reduce CTGF expression. Although
these results from primary cell culture clearly need in vivo
conﬁrmation, inhibition of the transforming growth factor
beta pathway is an attractive explanation for anti-ﬁbrogenic
effects attributed to caffeine.22
In conclusion, a useful tool for a comprehensive evaluation
of caffeine intake was applied and it indicated a beneﬁ-
cial effect, which requires caffeine intake above a threshold
of approximately 4-Brazilian coffee-cup/day. In addition, our
study showed that coffee intake has hepatoprotective beneﬁts
- an inverse association of the increased caffeine intake with
a lower risk of advanced ﬁbrosis - in treatment naïve Brazilian
patients with chronic hepatitis C even in different doses from
American and European intake.
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